RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.45−0.02 (-4.36%)
Close on Oct 19, 2026
- Market cap
- $5.94M
- P/E (TTM)
- –
- Dividend yield
- –
Reviva Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $5.90M | $166.30M |
| Enterprise Value | -$13.85M | $88.19M |
| PB Ratio | 0.39 | 2.03 |
| P/TBV Ratio | 0.39 | 2.29 |
Income (trailing twelve months)
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$13.48M | -$21.40M |
| Pretax Income | -$13.01M | -$14.34M |
| Net Income | -$13.02M | -$22.46M |
| EBITDA | -$13.48M | -$16.91M |
| EPS (Diluted) | -$2.32 | -$0.83 |
Returns
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -176.6% | -53.2% |
| Return on Assets (ROA) | -79.5% | -40.9% |
| Return on Capital Employed (ROCE) | -88.6% | -38.1% |
Balance sheet
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $19.89M | $61.43M |
| Total Debt | $144.09K | $118.52M |
| Net Cash (Debt) | $19.75M | $15.35M |
| Net Cash Per Share | $1.51 | $0.66 |
| Equity (Book Value) | $15.21M | $49.09M |
| Book Value Per Share | $1.16 | $1.37 |
| Tangible Book Value | $15.21M | $23.52M |
| Working Capital | $15.21M | $76.81M |
Financial position
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.56 | 3.34 |
| Quick Ratio | 3.35 | 2.44 |
| Debt / Equity | 0.01 | 0.52 |
| Interest Coverage | -2050.57 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$17.30M | -$12.35M |
Efficiency
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$930.16K | -$703.34K |
| Employee Count | 14 | 74 |
Dividends and yields
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -220.7% | -23.3% |
Shares
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 13,110,400 | 58,127,000 |
| Shares Change (YoY) | 243.7% | 10.9% |
| Shares Change (QoQ) | 2.34% | 0.54% |
| Shares Held by Institutions | 0.06% | 59.4% |
Taxes
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $11.70K | $79.87K |
Scores
| Measure | Reviva Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -13.21 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Reviva Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.